



U.S. Headquarters Location
800 Scudders Mill Rd
Plainsboro Township, NJ 08536



ESTABLISHED IN 1923,
COPENHAGEN, DENMARK



NEARLY 6,000 EMPLOYEES
ACROSS U.S. LOCATIONS

Novo Nordisk in the United States

At Novo Nordisk, we believe in change. We are parents, colleagues, neighbors and friends—people living with the complexities of serious diseases. And we believe in the combination of science and soul to help nurture each other back to good health.

For almost 100 years, we have been driving change to defeat diabetes, which has given us the experience and capability to help defeat other serious chronic diseases, including hemophilia, growth hormone disorders and obesity.

We work for a future where lives are not limited. To achieve this, we take the lead and continuously challenge the status quo by looking at change from new perspectives.

FAST FACTS



U.S. Headquarters in Plainsboro, NJ, with locations in seven states



Approximately 860 people working in R&D in the U.S.



Working within diabetes, obesity, hemophilia, and growth hormone disorders



Missy Kuhn
Type 2 Diabetes



\$8.6 BILLION TOTAL U.S. SALES IN 2019



Anders Kristensson
Type 2 Diabetes



Approximately 200,000 shareholders



More than 20 medicines marketed across therapeutic areas



Helping people afford our medicines through NovoCare®. Visit NovoCare.com or call 1.844.NOVO4ME (1.844.668.6463) for more



WEST LEBANON, NH



PLAINSBORO, NJ



CLAYTON and DURHAM, NC



SEATTLE, WA



INDIANAPOLIS, IN



FREMONT, CA




BOSTON, MA

THE TRIPLE BOTTOM LINE

The Triple Bottom Line principle guides how we do business. We always strive to conduct our activities in a financially, environmentally, and socially responsible way, because we know this is a prerequisite for a sustainable business and long-term value creation.

Our Triple Bottom Line approach

Financially responsible



Socially responsible ↔ Environmentally responsible





Actions that drive change

Making life-saving medicine is a significant responsibility — millions of people depend on us. However, to help defeat serious chronic diseases, we need to do more. Below are some of our activities and programs in the U.S.

changing diabetes®

Since Novo Nordisk was founded almost 100 years ago, we have been changing diabetes. Our key contribution is to discover and develop better medicines. However, to defeat this serious disease, we need to do more to address the unmet needs of people with diabetes.

changing hemophilia™

For more than three decades, Novo Nordisk has been committed to changing hemophilia. In addition to discovering and developing effective medicines, we work with our community partners to improve the lives of people with hemophilia.

changing obesity™

Obesity is a serious, chronic disease that affects more than 650 million people around the world. We're committed to improving the lives of people with obesity by changing how the world sees, prevents and treats the disease.

Cornerstones4Care®

Cornerstones4Care® is an online resource, available in English and Spanish, that supports people with diabetes with a personalized diabetes management program, including helpful information, interactive tools, and access to live diabetes educators and diabetes health coaches. Learn more at cornerstones4care.com

Truth About Weight™

Novo Nordisk developed the educational resource Truth About Weight™ to help people with obesity prepare for a productive conversation with their healthcare providers. TruthAboutWeight.com includes information about the science behind weight loss and offers tools to help assess weight management history, motivations, and triggers. Learn more at truthaboutweight.com

Novo Nordisk WORKS™

Novo Nordisk WORKS™ is a program that helps employers understand the value of chronic weight management in the workplace, and includes information to improve employee health and decrease health-related costs. Learn more at novonordiskworks.com

Obesity Care Advocacy Network

OCAN is a diverse group of organizations working together to change how we perceive and approach the problem of obesity in the U.S. through education, policy, and legislative efforts. Learn more at obesitycareadvocacynetwork.com

World Diabetes Day, World Hemophilia Day, Children's Growth Awareness Week, and National Obesity Care Week

Every year on World Diabetes Day (Nov. 14), World Hemophilia Day (Apr. 17), and World Obesity Day (Mar. 4), Novo Nordisk, together with international and local organizations, unites communities to raise awareness of these chronic conditions. We recognize Children's Growth Awareness Week in September. We are proud to be the founding sponsor of Obesity Care Week in March, an annual initiative aiming to create a society that understands, respects and accepts the complexities of obesity and values science-based care.

Corporate Giving

We're committed to supporting scientific and humanitarian causes that positively impact lives. For example, as part of our commitment to the Triple Bottom Line, Novo Nordisk launched Farmhouse to Your House, our partnership with community-based organizations, farms, and diabetes prevention programs in Mississippi. Farmhouse to Your House helps underserved people take proactive steps to manage their health with access to fresh, local produce, healthy recipes to cook for their families, and lessons on nutrition during regular meetings with diabetes educators. Learn more at farmhousetoyourhouse.com

Ask.Screen.Know®

Ask.Screen.Know® is a national education program that challenges Americans to find out about their risk of type 2 diabetes and raise awareness of the need for early screening. Learn more at askscreenknow.com

Diabetes Advocacy Alliance™ (DAA)

We are a founding member of the DAA, a coalition that aims to influence change in the U.S. healthcare system that improves diabetes prevention, detection, and care, and supports the development of pathways to cures for diabetes. Learn more at diabetesadvocacyalliance.org

Cities Changing Diabetes

Cities Changing Diabetes brings together medical and public health institutions, communities of faith, employers, insurers and non-profit organizations in cities throughout the world. The program launched in Houston in 2014, and today six initiatives reach, empower, and connect more than 75,000 Houstonians with diabetes prevention, care and management in the city. The Philadelphia program launched in late 2019; the ideation and selection process for new initiatives there is taking place this year. Learn more at citieschangingdiabetes.com

About Novo Nordisk in the U.S.:

Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases, including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 employees throughout the country. For more information, visit novonordisk.us, Facebook, Twitter, and Instagram.

STAY CONNECTED

   @NovoNordiskUS

For more information about Novo Nordisk's U.S. headquarters, visit: novonordisk.us

 [linkedin.com/company/novo-nordisk](https://www.linkedin.com/company/novo-nordisk)

Novo Nordisk Inc., 800 Scudders Mill Rd., Plainsboro, NJ 08536 U.S.A.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
©2020 Novo Nordisk US20NNG00054 Last Updated: July 2020